Navigation Links
CryoLife Receives CE Mark Approval for BioFoam(R) Hemostatic Technology
Date:8/4/2009

thetic(TM) Medical Adhesive is CE marked in the European Community for periosteal fixation following endoscopic browplasty (brow lift) in reconstructive plastic surgery and is distributed by a third party for this indication. CryoLife distributes HemoStase(TM), a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in the European Community and Canada for cardiac, vascular, and general surgery, subject to certain exclusions.

Statements made in this press release that look forward in time or that express management's beliefs, expectations or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the receipt and application of DOD funds and potential distribution timing and uses and applications for BioFoam. These future events may not occur as and when expected, if at all, and, together with the Company's business, are subject to various risks and uncertainties. These risks and uncertainties include that the Company may not receive all or any funds allocated under the DoD Appropriation, that BioFoam may not prove safe or effective for its intended uses, and that BioFoam development may not result in a commercial product on the time table anticipated, or at all. For additional risks impacting the Company's business, see the Risk Factors section of the Company's Annual Report on Form-10-K for the year ended December 31, 2008 and the Company's subsequent Form 10-Q filings. The Company does not undertake to update its forward-looking statements.

For additional information about the Company, visit CryoLife's Web Site: http://www.cryolife.com.

    Media Contacts:

    D. Ashley Lee                               Katie Brazel
    Executive Vice President,     
'/>"/>
SOURCE  CryoLife, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 

Related medicine news :

1. CryoLife Reports Record Quarterly Revenues of $28.2 Million
2. CryoLife Announces Release Date and Teleconference Call Details for 2009 Second Quarter Financial Results
3. Department of Defense Awards CryoLife $1.7 million to Develop BioFoam Hemostatic Technology
4. CryoLife Announces Release Date and Teleconference Call Details for First Quarter 2008 Financial Results
5. William F. Northrup, III, M.D. Joins CryoLife as Vice President of Medical Relations and Education
6. Cryolife Victim Responds to Untrue Assertions of Cryolife
7. CryoLife Announces Additions to Management Team
8. Watson Pharmaceuticals Receives FDA Approval for Generic Toprol XL(R) 25 MG and 50 MG
9. Savient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for KRYSTEXXA(TM)
10. Hanger Orthopedic Group, Inc. Receives Upgrade From Moodys Investors Service
11. PharmaForce Inc. Receives FDA Approval for First Generic of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension, USP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... (PRWEB) June 18, 2013 The ... battery powered, stand-alone device which can be used to ... stainless steel enclosure of the Temp1000IS comes with the ... with the IFC400 (sold separately) docking station ... for full communications. No more removal of end-caps to ...
(Date:6/18/2013)... 2013 Biomet hip lawsuit ... forward in a multidistrict litigation in U.S. District Court, ... According to court records, the litigation’s most recent status ... the Court also convened a motions hearing and a ... the Biomet hip replacement litigation. The proceeding’s next ...
(Date:6/18/2013)... Hospitals Case Medical Center clinical researchers have launched ... which will evaluate the ability of a patient,s ... end stage peripheral arterial disease (PAD). , ... Surgery at University Hospitals Case Medical Center,s Harrington ... at Case Western Reserve University School of Medicine, ...
(Date:6/18/2013)... June 18, 2013 The Elizabeth Glaser ... State and the U.S. President’s Emergency Plan for AIDS ... celebrate significant new milestones in the global effort to ... Kerry announced that as of June 2013, one million ... support. Since PEPFAR’s inception in 2003, EGPAF has ...
(Date:6/18/2013)... UT (PRWEB) June 18, 2013 Today, ... Health Reimbursement Accounts . Zane Benefits, which provides ... benefits, is the leader in defined contribution ... to Zane Benefits’ website, employees of a company who ... may have questions about how Health Reimbursement Accounts work. ...
Breaking Medicine News(10 mins):Health News:MadgeTech, Inc. Introduces the New Temp1000IS Intrinsically Safe High Temperature Data Logger 2Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 2Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 3Health News:UH Case Medical Center launches novel clinical trial using stem cells to prevent amputation 2Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 2Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 3Health News:Zane Benefits Publishes New Information on Health Reimbursement Accounts 2
... ... one-stop, flat-fee healthcare information technology and support, announced it is bringing ... the hiring of new Chief Healthcare Officer Joel Taylor. Taylor joins ... to practices and medical groups of all scopes and sizes, with ...
... Tuesday, October 13, in response to national calls for an ... announce their "patient-centered" plan for health care reform. The ... policy specialist Art Laffer, will be described in detail, together ... to the press (dial-in information is below). , ...
... ... for Cell Sense in vivo imaging agent , ... Pittsburgh, PA (Vocus) October 12, 2009 -- Celsense, Inc. announced today ... imaging reagent, Cell Sense CS-1000 (Cell Sense). , ,Celsense filed a Drug Master File (a “DMF”) ...
... ... help to otherwise untreatable symptoms of Multiple Sclerosis. , ... Camillo, CA (PRWEB) October 12, 2009 -- , , , ,The ... country a sometimes first in years relief from the relentless progressive symptoms of the disease. ...
... is forming the world,s first national centre for research into ... Arthritis Research Campaign and The University of Nottingham, it will ... cause of chronic pain which affects more than ten ... awarded funding of 2.5m over five years and the University ...
... Oct. 11 Canary Foundation, a nonprofit organization that ... its founder and chairman, Don Listwin, has been elected ... (BSA). Members are appointed to 5-year terms by the ... advice on science program policy, programs and initiatives to ...
Cached Medicine News:Health News:ITelagen Taps Joel Taylor as Chief Healthcare Officer New Executive to Spearhead EMR Implementations 2Health News:ITelagen Taps Joel Taylor as Chief Healthcare Officer New Executive to Spearhead EMR Implementations 3Health News:The Obamacare Alternative: 33 State Think Tanks Announce Patient-Centered Health Care Reforms 2Health News:Celsense, Inc Files FDA & EMEA Regulatory Submissions 2Health News:Celsense, Inc Files FDA & EMEA Regulatory Submissions 3Health News:People with Multiple Sclerosis are Proactively Improving their Walking, Energy Level, Confidence and Quality of Life 2Health News:People with Multiple Sclerosis are Proactively Improving their Walking, Energy Level, Confidence and Quality of Life 3Health News:National pain research center will bring hope to millions 2Health News:National pain research center will bring hope to millions 3Health News:National pain research center will bring hope to millions 4Health News:Canary Foundation's Don Listwin Appointed to National Cancer Institute's Board of Scientific Advisors 2
(Date:6/18/2013)... June 18, 2013 Valeant Pharmaceuticals International, Inc. ... "Company") announced today that VPII Escrow Corp., a newly ... launched its offer of approximately $3.2 billion aggregate principal ... will be due in 2021 and in 2023, with ... intends to use the net proceeds from the offering, ...
(Date:6/18/2013)... 18, 2013  Intercept Pharmaceuticals, Inc.  (NASDAQ: ... the development and commercialization of novel bile acid therapeutics ... of an underwritten public offering of 1,730,000 shares of ... $33.01 per share.  In addition, Intercept has granted the ... additional 259,500 shares of common stock. All ...
(Date:6/18/2013)... 2013 Valeant Pharmaceuticals International, Inc. (NYSE: ... previously announced public offering of common shares (the "Offering"). ... common shares at a price of $85.00 per share, ... Company will file a final prospectus supplement to its ... make a similar filing with the securities regulatory authorities ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2Valeant Pharmaceuticals Prices Public Offering Of Common Shares 2Valeant Pharmaceuticals Prices Public Offering Of Common Shares 3Valeant Pharmaceuticals Prices Public Offering Of Common Shares 4
... --,Allos Therapeutics, Inc. today announced that the ... opinion of the Committee for,Orphan Medicinal Products ... orphan drug designation to the Company's novel,antifolate ... with,peripheral T-cell lymphoma (PTCL). In July 2006, ...
... 16, 2007 /PRNewswire/ -- Sirion Therapeutics,Inc., an ... received orphan drug designation from the Food,and ... for the treatment of acute herpetic keratitis. ... in Europe under,the brand name of Virgan(R). ...
Cached Medicine Technology:Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission 2Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission 3Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission 4Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic,Drug to Treat Viral Eye Infection 2
... High performance fiberoptic imaging from ... ,Olympus has improved its fiberscope range, ... specifications and enhanced image performance. Olympus ... instruments for diagnosis and therapy in ...
... been designed with a large 2.8mm instrument ... This permits the selection of a wide ... procedures. In addition, this model features excellent ... and a bright, high-resolution image. It also ...
Indications For Usage: , Thoracic surgery. , Broncho-spirometry. , Thoracoscopies. , Differential or selective lung ventilation. ...
... Silbroncho is a double lumen tube made of ... tip., ,Due to the characteristics of silicone ... the patient at insertion. Furthermore, the tube will ... suitable for long term surgery., ,Silbronco is ...
Medicine Products: